Attention deficit hyperactivity disorder (ADHD) Course

Attention deficit hyperactivity disorder (ADHD) Course is organized by American Seminar Institute (ASI).

Description:
Highlights include diagnosing ADHD in children; limitations of current drug screening; Viloxazine for treatment of ADHD; ECT treatment; and more.

Accreditation:
Short Course: 10 AMA PRA Category 1 Credits™

Course Topics:
New Drug Update:
Evaluate the efficacy of semaglutide as an adjunct treatment for obesity in patients with type 2 diabetes; Analyze the American College of Cardiology/American Heart Association guidelines for the management of blood cholesterol; Interpret clinical data for novel therapies for hypercholesterolemia and hypertriglyceridemia in adults; Prescribe risk-lowering medications for children with familial hypercholesterolemia; Appraise the efficacy and safety of viloxazine for the treatment of ADHD. 

QUALIFIES FOR: Clinical Pharmacology:
Speakers: C. Wayne Weart, PharmD
Diagnosis and Management of ADHD in Adults
Identify factors that contribute to the development of ADHD in adults; Diagnose adults with ADHD based on criteria from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; Devise a treatment plan for ADHD in adults using pharmacologic and nonpharmacologic strategies and Recognize the differences in presentation of ADHD in adults and children and Treat psychiatric comorbidities that mimic ADHD in adults, eg, anxiety, depression.

Speakers: Timothy Wilens, MD
Update on Pediatric Psychopharmacology:
Incorporate the benefits and potential side effects of common psychotropic medications in pediatric patients; Choose optimal psychotropic medications based on psychiatric diagnosis and pharmacokinetics of the medication; Develop strategies for monitoring pediatric patients taking psychotropic medication; Employ strategies to find the optimal dose of selective serotonin reuptake inhibitors based on patient response and Use short-acting and extended-release medications for management of psychiatric diagnoses.

QUALIFIES FOR: Clinical Pharmacology:
Speakers: Jay Kothari, MD, and Andrew Riley, PhD
ADHD and Substance Abuse in Adults and Adolescents
Identify common psychiatric comorbidities in patients with ADHD; Summarize the long-term outcomes of early treatment for ADHD; Develop strategies for management of concurrent ADHD and substance use disorder in children and young adults; Counsel patients about the health and legal risks associated with stimulant misuse; Select pharmacologic therapy for ADHD to optimize response and minimize risk for misuse.

QUALIFIES FOR: Clinical Pharmacology, Substance Abuse:
Speakers: Timothy Wilens, MD
Electroconvulsive Therapy/Agitation
Develop an appropriate treatment course of ECT that is tailored to the needs of the patient; Determine the effectiveness of ECT compared with pharmacologic intervention; Summarize the indications and clinical relevance of ECT and the reasons for its underutilization; Evaluate ketamine use in the prehospital setting in the management of hyperactive delirium; Recommend appropriate medications for pharmacologic management of hyperactive delirium.